Historical mrna News Stories
Moderna Surge: $950M Patent Deal Sparks Rally Now!
Moderna (MRNA) jumped after settling LNP patent litigation with a $950M one-time payment and the FDA agreeing to review its seasonal flu mRNA-1010 application. Combined with a solid Q4 beat and optimistic guidance, these concrete developments removed major overhangs and drove a multiweek stock rally.
Moderna Rally: Patent Deal Sparks Stock Surge Up!!
Moderna stock jumped after a settlement over lipid nanoparticle patents and a regulatory milestone for its flu vaccine. The agreement reduces legal overhang, secures licensing terms without ongoing royalties, and sets a clear PDUFA date for mRNA-1010—catalysts that drove the recent double-digit gains in MRNA shares.
Moderna LNP Settlement, FDA Sets Flu PDUFA Date Q3
Moderna disclosed a major settlement resolving lipid‑nanoparticle patent litigation and secured FDA acceptance for its seasonal flu mRNA vaccine application with a PDUFA date in August 2026. Both developments triggered sharp stock moves and reduce key execution risks as the company pivots beyond COVID‑19 revenues.
Moderna Rally: FDA Reversal, Q4 Strength & Risks!!
Moderna (MRNA) saw a near-term rebound after the FDA agreed to review its mRNA flu shot application and the company posted stronger-than-expected Q4 results alongside aggressive cost cuts. Near-term catalysts include a March patent trial, oncology readouts later in 2026, and international regulatory reviews for combination vaccines.
Moderna FDA Reversal Spurs mRNA-1010 Rally Shares!
Moderna's shares jumped after the FDA reversed a refusal-to-file for its seasonal mRNA flu vaccine, mRNA-1010. Analyst target hikes, leadership shifts toward oncology, and cost cuts support the rally. This article summarizes the concrete regulatory, financial, and strategic developments that are driving near-term investor sentiment for MRNA.
FDA Reopens Review; Moderna's mRNA-1010 Boost Now!
Moderna regained regulatory momentum after the FDA agreed to review its mRNA-1010 seasonal flu vaccine, triggering a notable share uptick. Combined with quarterly financial guidance and an intensified oncology push, these concrete developments create near-term catalysts for MRNA stock.
Moderna Shock: FDA Blocks Flu Shot; Norges Buy Now
Moderna (MRNA) faced a major regulatory setback this week when the FDA issued a refusal-to-file for its mRNA flu vaccine mRNA-1010, citing comparator issues in elderly trials. Counterbalancing that blow, Norges Bank opened a large new position in Moderna and the company reports Q4 2025 results today—events that together create acute near-term volatility and longer-term pipeline inflection points.
Moderna Surges on Melanoma Data, Hits 52-Week High
Moderna (MRNA) rallied after preliminary 2025 financials and compelling five-year Phase 2 melanoma results for its personalized cancer vaccine (intismeran) combined with Keytruda. The company reported stronger-than-expected revenue, trimmed expenses, and an increased cash runway, while the clinical readout showed a 49% reduction in recurrence or death in high-risk melanoma. The twin catalysts pushed MRNA to new 52-week highs but left analysts cautious on valuation and execution risk.
MRNA Spike: Five-Year Melanoma Win Drives Moderna!
Moderna (MRNA) surged after five-year Phase 2b melanoma data showed a 49% recurrence risk reduction for its personalized mRNA cancer therapy with Merck. Simultaneous R&D cuts, a delayed cash break-even to 2028, and a pause on new infectious-disease vaccine studies reshape strategy and investor focus.
Moderna Stock Rally: Costs, Guidance, Funding Hit!
Moderna (MRNA) recently posted a sharp stock rally after reaffirming conservative revenue guidance and outlining cost-cutting targets at the J.P. Morgan Healthcare Conference. Strong technical indicators contrasted with a U.S. $500M cut to public mRNA research funding — a development that raises execution risk for Moderna’s therapeutic programs even as vaccine commercialization efforts move forward.
Moderna Spike: mRNA-1010 Filings Propel Stock Rise
Moderna’s shares jumped after the company filed mRNA-1010 seasonal flu vaccine applications across major regulators. The coordinated filings and clearer commercialization pathway pushed investor sentiment higher, signaling a strategic shift beyond COVID-19 products.
Moderna Gains: $54M CEPI Deal, RS Rating Up
Moderna (MRNA) received $54.3M from CEPI to support a Phase 3 bird‑flu vaccine trial and saw a modest IBD Relative Strength upgrade. These developments reduce program risk and improve technical price momentum, though revenue declines and execution milestones remain key near‑term drivers for the Nasdaq‑100 stock.
Moderna Rally: EMA Nod and Technical Breakout 2025
Moderna gained momentum after the EMA's CHMP gave a positive opinion on its next-gen COVID candidate mNEXSPIKE and technical indicators flagged a potential breakout. Investors should weigh near-term catalysts against weak recent fundamentals and growing sector consolidation.
Moderna Secures CEPI Grant; Shares Under Pressure!
Moderna won a $54.3M CEPI award to advance its mRNA‑1018 bird flu vaccine into a pivotal trial, while new FDA vaccine standards and a string of analyst downgrades have pushed MRNA shares toward 52‑week lows. This article summarizes the funding, trial plans, regulatory impact, and what investors should monitor next.
Moderna Falls After FDA Memo on Pediatric Risk
A leaked internal FDA memorandum proposing tougher vaccine approval standards and flagging potential pediatric myocarditis deaths rattled investors this week. Moderna shares fell sharply, dragging other vaccine names lower and raising questions about near-term regulatory hurdles for mRNA-based products.
Moderna Shorted Heavily; $140M Backs Norwood Build
Recent reporting shows Moderna has become one of the most heavily shorted large-cap names while simultaneously committing $140 million to complete a domestic mRNA manufacturing site in Norwood. This article explains the short-interest dynamics, the strategic manufacturing investment, and how these developments affect MRNA stock.
Moderna Boosts Liquidity; Q3 Revenue Pressures Q4!
Moderna secured a $1.5B non-dilutive credit facility, committed $140M to complete U.S. mRNA manufacturing, and reported a Q3 revenue decline with narrowed full-year guidance. These concrete actions strengthen liquidity and operational control but leave near-term revenue and profitability challenges that investors should weigh against upcoming clinical and commercial catalysts.
Moderna Hits Turbulence: Q3 Results, CMV Cut, Vote
Moderna's recent week brought a mixed signal: a Q3 revenue beat but narrower guidance, termination of the CMV program, and a shareholder vote on an option exchange that could reduce dilution. Analysts remain cautious while institutional moves show both trimming and new interest.
Moderna Gains FDA Nod; US Cancels $766M Flu Deal!!
Moderna won FDA approval for its next‑generation COVID vaccine mNEXSPIKE while the U.S. government simultaneously cancelled roughly $766M in bird‑flu vaccine contracts — a one‑two punch that produced mixed signals for MRNA stock, combining immediate commercial upside with a loss of government funding and political headwinds.